Biotecnol Gained Access to PER.C6® for Antibody Production
DSM Biologics and Crucell will receive license and maintenance fees.!--h2>
Biotecnol obtained license rights to DSM Biologics’ and Crucell’s PER.C6® human cell line for preclinical and Phase I development of its antibody products, which are composed of Tribodies™ and compact antibodies.
"We believe that by adopting the PER.C6 production platform, we will be able to develop our products in a robust, cost-efficient, and most importantly, in a timely way, due to its characteristics and ease of manipulation,” says Pedro de Noronha Pissarra, CEO of Biotecnol.
Under the terms of the agreement, Biotecnol will make license payments and annual maintenance fees in exchange for certain rights.